The significance of α-Synuclein, Amyloid-β and Tau pathologies in Parkinson's disease progression and related dementia
<p><strong>Background:</strong> Dementia is one of the milestones of advanced Parkinson’s disease (PD), with its neuropathological substrate still being a matter of debate, particularly regarding its potential mechanistic implications.</p> <p><strong>Objective:<...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
Karger
2013
|
| _version_ | 1797079805974282240 |
|---|---|
| author | Compta, Y Parkkinen, L Kempster, P Selikhova, M Lashley, T Holton, J Lees, A Revesz, T |
| author_facet | Compta, Y Parkkinen, L Kempster, P Selikhova, M Lashley, T Holton, J Lees, A Revesz, T |
| author_sort | Compta, Y |
| collection | OXFORD |
| description | <p><strong>Background:</strong> Dementia is one of the milestones of advanced Parkinson’s disease (PD), with its neuropathological substrate still being a matter of debate, particularly regarding its potential mechanistic implications.</p> <p><strong>Objective:</strong> The aim of this study was to review the relative importance of Lewyrelated α-synuclein and Alzheimer’s tau and amyloid-β (Aβ) pathologies in disease progression and dementia in PD.</p> <p><strong>Methods:</strong> We reviewed studies conducted at the Queen Square Brain Bank, Institute of Neurology, University College London, using large PD cohorts.</p> <p><strong>Results:</strong> Cortical Lewy- and Alzheimer-type pathologies are associated with milestones of poorer prognosis and with non-tremor predominance, which have been, in turn, linked to dementia. The combination of these pathologies is the most robust neuropathological substrate of PD-related dementia, with cortical Aβ burden determining a faster progression to dementia.</p> <p><strong>Conclusion:</strong> The shared relevance of these pathologies in PD progression and dementia is in line with experimental data suggesting synergism between α-synuclein, tau and Aβ and with studies testing these proteins as disease biomarkers, hence favouring the eventual testing of therapeutic strategies targeting these proteins in PD.</p> |
| first_indexed | 2024-03-07T00:51:02Z |
| format | Journal article |
| id | oxford-uuid:866c9dc8-1646-4da3-b0e8-23e6fa662cf2 |
| institution | University of Oxford |
| last_indexed | 2024-03-07T00:51:02Z |
| publishDate | 2013 |
| publisher | Karger |
| record_format | dspace |
| spelling | oxford-uuid:866c9dc8-1646-4da3-b0e8-23e6fa662cf22022-03-26T22:03:49ZThe significance of α-Synuclein, Amyloid-β and Tau pathologies in Parkinson's disease progression and related dementiaJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:866c9dc8-1646-4da3-b0e8-23e6fa662cf2Symplectic Elements at OxfordKarger2013Compta, YParkkinen, LKempster, PSelikhova, MLashley, THolton, JLees, ARevesz, T<p><strong>Background:</strong> Dementia is one of the milestones of advanced Parkinson’s disease (PD), with its neuropathological substrate still being a matter of debate, particularly regarding its potential mechanistic implications.</p> <p><strong>Objective:</strong> The aim of this study was to review the relative importance of Lewyrelated α-synuclein and Alzheimer’s tau and amyloid-β (Aβ) pathologies in disease progression and dementia in PD.</p> <p><strong>Methods:</strong> We reviewed studies conducted at the Queen Square Brain Bank, Institute of Neurology, University College London, using large PD cohorts.</p> <p><strong>Results:</strong> Cortical Lewy- and Alzheimer-type pathologies are associated with milestones of poorer prognosis and with non-tremor predominance, which have been, in turn, linked to dementia. The combination of these pathologies is the most robust neuropathological substrate of PD-related dementia, with cortical Aβ burden determining a faster progression to dementia.</p> <p><strong>Conclusion:</strong> The shared relevance of these pathologies in PD progression and dementia is in line with experimental data suggesting synergism between α-synuclein, tau and Aβ and with studies testing these proteins as disease biomarkers, hence favouring the eventual testing of therapeutic strategies targeting these proteins in PD.</p> |
| spellingShingle | Compta, Y Parkkinen, L Kempster, P Selikhova, M Lashley, T Holton, J Lees, A Revesz, T The significance of α-Synuclein, Amyloid-β and Tau pathologies in Parkinson's disease progression and related dementia |
| title | The significance of α-Synuclein, Amyloid-β and Tau pathologies in Parkinson's disease progression and related dementia |
| title_full | The significance of α-Synuclein, Amyloid-β and Tau pathologies in Parkinson's disease progression and related dementia |
| title_fullStr | The significance of α-Synuclein, Amyloid-β and Tau pathologies in Parkinson's disease progression and related dementia |
| title_full_unstemmed | The significance of α-Synuclein, Amyloid-β and Tau pathologies in Parkinson's disease progression and related dementia |
| title_short | The significance of α-Synuclein, Amyloid-β and Tau pathologies in Parkinson's disease progression and related dementia |
| title_sort | significance of α synuclein amyloid β and tau pathologies in parkinson s disease progression and related dementia |
| work_keys_str_mv | AT comptay thesignificanceofasynucleinamyloidbandtaupathologiesinparkinsonsdiseaseprogressionandrelateddementia AT parkkinenl thesignificanceofasynucleinamyloidbandtaupathologiesinparkinsonsdiseaseprogressionandrelateddementia AT kempsterp thesignificanceofasynucleinamyloidbandtaupathologiesinparkinsonsdiseaseprogressionandrelateddementia AT selikhovam thesignificanceofasynucleinamyloidbandtaupathologiesinparkinsonsdiseaseprogressionandrelateddementia AT lashleyt thesignificanceofasynucleinamyloidbandtaupathologiesinparkinsonsdiseaseprogressionandrelateddementia AT holtonj thesignificanceofasynucleinamyloidbandtaupathologiesinparkinsonsdiseaseprogressionandrelateddementia AT leesa thesignificanceofasynucleinamyloidbandtaupathologiesinparkinsonsdiseaseprogressionandrelateddementia AT reveszt thesignificanceofasynucleinamyloidbandtaupathologiesinparkinsonsdiseaseprogressionandrelateddementia AT comptay significanceofasynucleinamyloidbandtaupathologiesinparkinsonsdiseaseprogressionandrelateddementia AT parkkinenl significanceofasynucleinamyloidbandtaupathologiesinparkinsonsdiseaseprogressionandrelateddementia AT kempsterp significanceofasynucleinamyloidbandtaupathologiesinparkinsonsdiseaseprogressionandrelateddementia AT selikhovam significanceofasynucleinamyloidbandtaupathologiesinparkinsonsdiseaseprogressionandrelateddementia AT lashleyt significanceofasynucleinamyloidbandtaupathologiesinparkinsonsdiseaseprogressionandrelateddementia AT holtonj significanceofasynucleinamyloidbandtaupathologiesinparkinsonsdiseaseprogressionandrelateddementia AT leesa significanceofasynucleinamyloidbandtaupathologiesinparkinsonsdiseaseprogressionandrelateddementia AT reveszt significanceofasynucleinamyloidbandtaupathologiesinparkinsonsdiseaseprogressionandrelateddementia |